Mauna Kea Technologies Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults
03 April 2024 - 2:59AM
Business Wire
Italy becomes the third country to launch a
Cellvizio Center of Excellence following the Metrodora Institute in
the U.S. and several other centers in Germany
Another key milestone in a global initiative
to expand centers for Cellvizio Food Intolerance programs in key
countries
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT)
(Paris:ALMKT), inventor of Cellvizio®, the multidisciplinary probe
and needle-based confocal laser endomicroscopy (p/nCLE) platform,
today announced the opening of the first Italian Center of
Excellence for the use of Cellvizio to identify and treat food
intolerances in adult patients suffering from Irritable Bowel
Syndrome (IBS). The Cellvizio Food Intolerance Test (C-FIT) is now
performed by Dr. Alberto Larghi, a leading Gastroenterologist, at
the UPMC Salvator Mundi International Hospital in Rome, Italy.
With the introduction of C-FIT, Mauna Kea Technologies is
setting a new standard in the accurate, real-time diagnosis of food
intolerance, a condition that affects millions of people worldwide,
often without proper diagnosis. In Italy in particular, the number
of patients looking for solutions in this area is very high with
over 1 million food intolerance related internet searches per
month, more than in Germany and France.
This initiative at the UPMC Salvator Mundi International
Hospital is part of a global strategic expansion plan to establish
Centers of Excellence, building on Metrodora Institute's
establishment in March1, which are set to spearhead the rapid
adoption of the practice across several key countries.
"We are very excited to have UPMC Salvator Mundi International
Hospital serve as our Center of Excellence for the Cellvizio Food
Intolerance Test in Italy, another significant step forward in the
scaling of the use of Cellvizio in the ever-expanding food
intolerance market. Our ambition in this field is very high, and
opening two reference centers in less than two months in two major
countries for IBS is a testament to our determination to be at the
forefront of gastrointestinal health services", said Sacha
Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea
Technologies. "There is an urgent, unmet need for the immense
pool of IBS patients who endure debilitating daily complications.
We are very pleased with the strong interest from a growing number
of hospitals and clinics to launch a Food Intolerance Program with
Cellvizio as its central component."
“Many patients live with undiagnosed food intolerances, simply
because existing testing methods cannot identify the underlying
issues. The Cellvizio Food Intolerance procedure is a simple,
visual and clinically proven way to determine whether the patient
has a previously undetected food intolerance. I couldn’t be more
excited to be the first in Italy to perform this procedure and to
establish the first Center of Excellence in our country”, said
Dr. Alberto Larghi, Gastroenterology and Digestive Endoscopy
Specialist. “My vision is that by adopting novel technologies
like Cellvizio, we can collectively improve the lives of the
patients we serve.”
Next financial release: Financial results Full Year 2023
and Trading Update Q1 2024, on April 25, 2024 after market
close.
***
About IBS & Food Intolerance Irritable bowel syndrome
affects approximately 10-15% of the European population, although
prevalence rates vary depending on the classification used and the
country surveyed. Moreover, up to 70% of individuals with irritable
bowel syndrome may not have been formally diagnosed, a condition
reportedly linked to atypical food intolerance in the majority of
cases, characterized by a group of symptoms including abdominal
pain, bloating, and changes in bowel habits (diarrhea,
constipation, or both). This condition significantly affects the
quality of life of those affected who often face a protracted and
distressing journey of medical consultation that could last 2 to 3
years on average with no guaranteed path to identifying the
underlying cause of their symptoms.
About Mauna Kea Technologies Mauna Kea Technologies is a
global medical device company that manufactures and sells
Cellvizio®, the real-time in vivo cellular imaging platform. This
technology uniquely delivers in vivo cellular visualization which
enables physicians to monitor the progression of disease over time,
assess point-in-time reactions as they happen in real time,
classify indeterminate areas of concern, and guide surgical
interventions. The Cellvizio® platform is used globally across a
wide range of medical specialties and is making a transformative
change in the way physicians diagnose and treat patients. For more
information, visit www.maunakeatech.com.
Disclaimer This press release contains forward-looking
statements about Mauna Kea Technologies and its business. All
statements other than statements of historical fact included in
this press release, including, but not limited to, statements
regarding Mauna Kea Technologies' financial condition, business,
strategies, plans and objectives for future operations are
forward-looking statements. Mauna Kea Technologies believes that
these forward-looking statements are based on reasonable
assumptions. However, no assurance can be given that the
expectations expressed in these forward-looking statements will be
achieved. These forward-looking statements are subject to numerous
risks and uncertainties, including those described in Chapter 3 of
Mauna Kea Technologies' 2022 Universal Registration Document filed
with the Autorité des marchés financiers (AMF) on June 28, 2023
under number D-23-0545, which is available on the Company's website
(www.maunakeatech.fr), as well as the risks associated with changes
in economic conditions, financial markets and the markets in which
Mauna Kea Technologies operates. The forward-looking statements
contained in this press release are also subject to risks that are
unknown to Mauna Kea Technologies or that Mauna Kea Technologies
does not currently consider material. The occurrence of some or all
of these risks could cause the actual results, financial condition,
performance or achievements of Mauna Kea Technologies to differ
materially from those expressed in the forward-looking statements.
This press release and the information contained herein do not
constitute an offer to sell or subscribe for, or the solicitation
of an order to buy or subscribe for, shares of Mauna Kea
Technologies in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. The
distribution of this press release may be restricted in certain
jurisdictions by local law. Persons into whose possession this
document comes are required to comply with all local regulations
applicable to this document.
1 “Mauna Kea Technologies Partners With Metrodora To Create
First U.S. Center Of Excellence For The Use Of Cellvizio® To
Identify And Treat Food Intolerance In Adults”, March 6, 2024
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240402122652/en/
Mauna Kea Technologies investors@maunakeatech.com
NewCap - Investor Relations Aurélie Manavarere / Thomas
Grojean +33 (0)1 44 71 94 94 maunakea@newcap.eu
Mauna Kea Technologies (EU:ALMKT)
Historical Stock Chart
From Apr 2024 to May 2024
Mauna Kea Technologies (EU:ALMKT)
Historical Stock Chart
From May 2023 to May 2024